BOEHRINGER-INGELHEIM
Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.
Both companies will initially focus on developing the compound for the treatment of IPF, an area of high-unmet medical need and one of the key focus areas of Boehringer Ingelheim. Boehringer Ingelheim has developed OFEV® (nintedanib), an antifibrotic drug shown to slow disease progression by reducing lung function decline and currently approved for the treatment of IPF in more than 70 countries around the world including the US, the EU and Japan.
IPF is a rare, debilitating and fatal lung disease affecting approximately three million people worldwide. It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and breathing difficulties. BBT-877 inhibits autotaxin, an enzyme mediating a key pro-fibrotic event in multiple cell types. It has shown a promising safety and efficacy profile in pre-clinical models for fibrosing interstitial lung diseases and potential for combination with the current standard of care.
Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit said, “We look forward to working with the team at Bridge Biotherapeutics to develop a new treatment option for patients with IPF. This new collaboration complements our growing pipeline in fibrosing interstitial lung diseases and is a sign of our determination to bring the next generation of treatment options to these patients.”
“Bridge Biotherapeutics is pleased to partner with Boehringer Ingelheim, a recognized leader in IPF. The expertise of Boehringer Ingelheim will ensure that our novel therapeutic candidate can be developed to potentially address unmet medical needs of IPF patients worldwide,” said James Lee, CEO of Bridge Biotherapeutics.
“This is a transformational event for Bridge Biotherapeutics with a total potential value in excess of EUR 1.1 billion. It is a testament to the company’s excellence in the development of novel therapeutics for disease areas with high unmet medical need,” commented B. Chris Kim, PhD, a board member of Bridge Biotherapeutics based in Cambridge, Massachusetts.
Bridge Biotherapeutics will receive upfront and near term payments of EUR 45 million and is eligible to receive up to more than EUR 1.1billion in potential payments based upon the successful achievement of specified development, regulatory, and commercial milestones and staggered, up to double digit royalties.
Please click on the link for Notes to Editors:
http://www.boehringer-ingelheim.com/press-release/collaboration-bridge-biotherapeutics
View source version on businesswire.com: https://www.businesswire.com/news/home/20190718005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ElevenLabs-Powered Chroma Awards Opens Call For Submissions, With November 3 Deadline15.9.2025 15:00:00 CEST | Press release
Creator-Led Global AI Film, Music Video, and Games CompetitionUniting the Global AI Creative Community Chroma Awards, a groundbreaking AI Film, Music Video, and Games competition organized by ElevenLabs, the leading AI audio research and product company, announced today that submissions are open for its inaugural competition, with a November 3 deadline. Competition participants can access free trials of AI tools provided by sponsors starting today at https://pack.chromaawards.com/. The Chroma Awards was established with the mission to educate, empower, and spotlight the next generation of artists and showcase how AI can empower human creativity. The competition is organized by ElevenLabs and presented by Google Cloud, Freepik, fal, Dreamina AI, and CapCut. “Through this initiative we hope to unite creators, communities, and companies across the world to bring emerging technology and creative talent together in dialogue,” said Matty Shimura, Chroma Awards. “We’re incredibly grateful to
33 Innovators Join Morgan Stanley Inclusive & Sustainable Ventures Cohort15.9.2025 14:08:00 CEST | Press release
Accelerator’s expanded focus includes sustainable solutions and support for nonprofits 2025 cohort comprised of 33 early-stage innovators from the Americas and EMEA Five-month program to provide founders with $250,000 (£250,000), as well as mentorship and growth resources Morgan Stanley (NYSE: MS) today announced the global cohort of its Inclusive & Sustainable Ventures (MSISV). With founders from the Americas and Europe, the Middle East and Africa (EMEA), the 2025 MSISV cohort will support 29 startups in its Lab and four emerging nonprofits in its Collaborative, two in-house accelerators that will run over the next five months. Selected from thousands of applications, the 33 organizations will engage in a tailored entrepreneurship curriculum and receive mentorship and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners. The firm will invest $250,000 (£250,000 in EMEA) in each startup and provide each nonprofit with a $250,000 grant. “Morgan Stan
Helmholtz Munich and Parse Biosciences GigaLab Generate World’s Largest Human Lung Tissue Perturbation Atlas15.9.2025 14:00:00 CEST | Press release
Researchers aim to identify cellular circuit mechanisms and generate a dataset to fuel AI-driven foundational research of lung biology Helmholtz Munich and Parse Biosciences today announced a strategic partnership to generate the world’s broadest lung disease perturbation atlas, powered by Parse Biosciences’ GigaLab platform. Using a human lung ex-vivo tissue slice culture model from normal control donor lungs as well as explant lung tissues from patients with chronic lung disease, the study aims to identify novel targets and cell circuits in lung health and disease by characterizing disease-specific responses of cells to 900 pharmacological interventions. Prof Herbert Schiller, Director of Helmholtz Munich’s Precision Regenerative Medicine Research Unit, and a leading researcher on lung biology and disease, will head this ambitious initiative. “Measuring the effects of drug treatments at single cell level directly in human lung tissue at scale, will help us to find strategies that imp
AmTrust Financial Services and Blackstone Credit & Insurance Enter Into Strategic Transaction for AmTrust’s Global MGA and Fee Businesses15.9.2025 14:00:00 CEST | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions Global MGA and Fee Businesses for Accelerated GrowthAmTrust President Adam Karkowsky to Leave to Become Chairman and CEO of New Multinational MGA Platform AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced a definitive agreement under which AmTrust and funds managed by BXCI will partner in the spin-off of certain of AmTrust’s Managing General Agencies (“MGAs”) and fee businesses in the U.S., United Kingdom, and Continental Europe into a new, independent company. AmTrust and the newly formed company will enter into a ten-year capacity agreement through which AmTrust will remain underwriter of the existing books of business offered through the MGAs. The agreement includes seven AmTrust subsidiaries: ANV, Risico, Collegiate, AmTrust Nordic, Arc Legal, Qualis, and Abacus. These businesses provide diverse risk and
Red Sea Global Unveils Shura Island: A New Era of Luxury Tourism Begins This September15.9.2025 13:30:00 CEST | Press release
- Iconic brands SLS, EDITION, and InterContinental prepare to welcome first guests to the heart of The Red Sea - Shura Links, the championship 18-hole golf course, is also set to welcome players, offering a world-class golfing experience - Shura Island is also host to a collection of exclusive homes, offering a rare opportunity to own part of the luxury destination Red Sea Global (RSG), the developer behind regenerative tourism destinations The Red Sea and AMAALA, has announced that the first resorts and attractions on Shura Island will begin opening to guests in the coming weeks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915221123/en/ The EDITION Red Sea, opening soon on Shura Island features 240 elegantly designed rooms and suites. Phase one of the launch includes the debut of SLS, EDITION, and InterContinental hotels, along with Shura Links, Saudi Arabia’s first island golf course. This moment marks a major milest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom